CNX Therapeutics | B Corp™ Certified

Pharmaceutical ManufacturingEngland, United Kingdom51-200 Employees

CNX Therapeutics is a European specialty pharmaceutical company focused on improving patient access to essential medicines through licensing and distribution of a portfolio spanning CNS, critical care, and other conditions. It operates directly and via strategic partnerships, distributing medicines in more than 60 countries. It is based in London, UK, and holds B Corp certification, reflecting a governance and social purpose framework.

Its customer base includes healthcare providers and patients across Europe and beyond, with the aim of being a partner of choice through commercial excellence and patient focus. A notable development in 2026 was the acquisition of rights to Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia. The company has also grown through leadership changes in 2025–2026 to support its growth strategy, including appointments of a chair, a non-executive director, and a chief corporate development officer.

Sign up for free to view info

Email Format Employee directory